Although the OS data for patients undergoing adjuvant alectinib in the ALINA study are still immature, a combined analysis with existing data, following extended follow-up, suggests a considerable improvement in total survival for early-stage ALK-positive NSCLC patients treated with alectinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.